AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Phase 1

Recruiting

• Conditions: Mesial Temporal Lobe Epilepsy

• Registration Number: NCT06063850
• Lead Sponsor: UniQure Biopharma B.V.

Brief Summary

The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).

Detailed Description

In this first clinical study of AMT-260, two dose levels will be studied to find the best dose of AMT-260. All eligible participants will receive AMT-260 at one of the two dose levels (i.e., there is no placebo in this study).

AMT-260 is intended for a one-time administration, without the need to remove or destroy any part of the brain. Participation in this study would not prevent later pursuit of other treatment options.

Participants will be monitored through study site visits, telephone calls, blood tests, and questionnaires about how their seizures affect daily life. Participants will record seizures using an electronic seizure diary.

Study Timeline

• Study First Submitted: 2023-09-01
• Study First Submitted QC: 2023-09-25
• Study First Posted: 2023-10-03
• Study Start: 2024-06-12
• Status Verified: 2025-05
• Last Update Submitted: 2025-07-03
• Last Update Posted: 2025-07-09
• Primary Completion: 2026-11-30
• Study Completion: 2031-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Diagnosis of unilateral refractory MTLE
• History of seizures with an average of ≥ 2 documented focal impaired awareness seizures or focal to bilateral tonic-clonic seizures per 30-day period in the 3 months prior to screening.
• On a stable type and dose regimen of up to a maximum of 4 approved Anti Seizure Drugs for at least 6 months prior to screening.
• Confirmed unilateral hippocampal pathology and concordant unilateral seizure focus
• No evidence of focal neurocognitive dysfunction, inconsistent with disease pathology- related MRI and/or (18F)FDG-PET findings.
• Women of childbearing potential (WOCBP) and fertile male subjects must be willing and able to use highly effective methods of birth control consistently and correctly throughout the study.
• For WOCBP only: Negative pregnancy test.

Exclusion Criteria

• Implanted devices that would contraindicate MRI; MRI-compatible devices must be implanted ≥3 months prior to Screening (vagus nerve stimulation devices will be up to discretion of the Investigator).
• Any other contraindications for generalized anesthesia or surgery.
• Medications that could confound clinical (e.g., antipsychotic medication and anti-viral therapy) and laboratory evaluations or could affect a participant's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule.
• Any seizures with contralateral or extra-temporal ictal onset captured on EEG.
• Dementia or other progressive neurological disorders and progressive brain lesions.
• Previous major disease-unrelated neurosurgical intervention due to intracranial tumor, trauma, or bleeding and/or history of previous intracranial surgery for treatment of epileptic seizures, not including diagnostic stereo-EEG.
• Magnetic resonance imaging evidence of epileptogenic, extra-temporal lesions, or dual temporal lobe pathology.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Primary Outcome Measures

Name	Time	Method
To evaluate the safety and tolerability of AMT-260 in adults with unilateral refractory MTLE.	1 year	Occurrence of Adverse Events during the period of 1 year after AMT-260 administration, including seriousness, severity, and causal relationship to AMT-260.

Secondary Outcome Measures

Name	Time	Method
To evaluate first signs of efficacy of AMT-260.	1 year	Change in seizure frequency, comparing baseline to the 1 year period after AMT-260 administration.
To evaluate the biodistribution properties of AMT-260.	1 year	Blood, urine, saliva, and CSF samples will be collected and evaluated for vector DNA shedding at each timepoint.

Trial Locations

Locations (19)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Mayo Clinic Arizona; 🇺🇸 Phoenix, Arizona, United States

Stanford University; 🇺🇸 Palo Alto, California, United States

Mayo Clinic Florida; 🇺🇸 Jacksonville, Florida, United States

Kansas University Medical Center; 🇺🇸 Kansas City, Kansas, United States

Johns Hopkins School of Medicine; 🇺🇸 Baltimore, Maryland, United States

Midatlantic Epilepsy and Sleep Center; 🇺🇸 Bethesda, Maryland, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States

Corewell Health; 🇺🇸 Grand Rapids, Michigan, United States

Scroll for more (9 remaining)